Cowen Raises Price Target on Seattle Genetics (SGEN) Following 2Q15
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high on Alphabet boost, Mideast negotiation hopes
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Seattle Genetics Reports Second Quarter 2015 Financial Results
July 30, 2015 4:02 PM EDT-Total Second Quarter 2015 Revenues of $77.1 Million, Including Record $55.1 Million in ADCETRIS® (Brentuximab Vedotin) U.S. and Canada Net Sales-
-ADCETRIS 2015 Net Sales Guidance Increased to a Range of $210 Million to $220 Million-
-Potential ADCETRIS Label Expansion through AETHERA Supplemental Biologics License Application (BLA) Currently Under FDA Priority Review; PDUFA Action Date August 18, 2015-
-Additional Clinical Data from Multiple Pipeline Programs Expected In Next Six to Nine Months, Including SGN-CD33A for Acute Myeloid Leukemia-
-Conference Call Today at 4:30 p.m. ET-... More
